3/19
10:44 am
goss
VALERIO THERAPEUTICS: List of the Board Members Positions Held in Other Companies as of March 19, 2025 [Yahoo! Finance]
Low
Report
VALERIO THERAPEUTICS: List of the Board Members Positions Held in Other Companies as of March 19, 2025 [Yahoo! Finance]
3/18
08:06 am
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
3/14
10:12 am
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
Medium
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
3/13
04:01 pm
goss
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
High
Report
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
3/7
05:30 pm
goss
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
3/3
05:28 am
goss
With 60% ownership of the shares, Gossamer Bio, Inc. (NASDAQ:GOSS) is heavily dominated by institutional owners [Yahoo! Finance]
Medium
Report
With 60% ownership of the shares, Gossamer Bio, Inc. (NASDAQ:GOSS) is heavily dominated by institutional owners [Yahoo! Finance]
2/13
07:49 pm
goss
https://seekingalpha.com/article/4758211-gossamer-bio-stock-good-speculative-buy-seralutinib-pah-ph-ild [Seeking Alpha]
Medium
Report
https://seekingalpha.com/article/4758211-gossamer-bio-stock-good-speculative-buy-seralutinib-pah-ph-ild [Seeking Alpha]
2/7
05:30 pm
goss
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/3
07:01 am
goss
Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
Medium
Report
Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
1/30
08:18 am
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
1/28
07:01 am
goss
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
Medium
Report
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
1/7
05:30 pm
goss
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)